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Background: Many patients with gastric gastrointestinal stromal tumor (GIST) and synchronous gastric cancer have
been described, most in single case studies. We retrospectively investigated the clinicopathologic features and
prognostic effects of gastric GIST in patients with synchronous gastric cancer.
Methods: The study enrolled 170 patients with gastric GIST, who had undergone complete surgical resection (R0)
from January 2000 to December 2011. Forty-two patients had synchronous gastric cancer (CA Group), whereas 128
did not (Non-CA Group). The clinicopathologic features and potential prognostic factors in the two groups were
compared.
Results: Patients in the CA Group had more obvious symptoms, but a lower rate of preoperative diagnosis of
gastric GIST (P <0.05). The two groups differed significantly in gender, age, greatest tumor diameter, risk
stratification, tumor-associated ulcers, and CD117 and CD34 expression (P <0.05 each). Univariate analysis showed
that age, risk stratification, postoperative oral imatinib and synchronous gastric cancer were predictive factors of
survival (P <0.05). Cox regression analysis showed that risk stratification, postoperative oral imatinib and synchronous
gastric cancer were independent predictors of survival (P <0.05). Stratified analysis showed that the 5-year overall
survival rate was lower in patients with synchronous gastric cancer than in those without synchronous gastric
cancer.
Conclusions: Gastric GIST with synchronous gastric cancer had a lower rate of preoperative diagnosis, with correct
diagnosis often missed. Survival, however, depended primarily on the gastric cancer.
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Gastrointestinal stromal tumor (GIST) is the most com-
mon mesenchymal tumor of the gastrointestinal tract,
with the most frequent site being the stomach. Since the
first report of synchronous epithelial and stromal tumors
in the stomach in 2000, [1] many patients with gastric
GIST and synchronous gastric cancer have been de-
scribed, most in single case studies [2-8]. However, little
is known about the synchronous GIST and gastric can-
cer. Its clinicopathologic characteristics and prognostic
factors are unclear. We therefore retrospectively com-
pared clinicopathologic findings and prognostic factors
in patients with primary GIST with those in patients
with primary GIST and synchronous gastric cancer.* Correspondence: hcmlr2002@163.com
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Between January 2000 and December 2011, 194 patients
diagnosed with primary gastric GIST underwent surgi-
cal treatment at the Affiliated Union Hospital of Fujian
Medical University, Fuzhou, China. Patients were included
if their diagnosis of GIST was confirmed pathologically
after surgery and if they underwent initial complete surgi-
cal resection (R0) for GIST and/or gastric cancer at our
hospital. Patients were excluded if they had malignancies
other than gastric cancer along with gastric GIST; if they
had distant metastases before surgery; or if their patho-
logical diagnosis was incomplete. Of the 170 patients
enrolled, 42 had synchronous gastric cancer (CA Group),
and 128 did not (Non-CA Group).
Combinations of abdominal ultrasonography, com-
puted tomography/magnetic resonance imaging, gastros-
copy/endoscopic ultrasound were used for diagnosis of. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Metastatic disease was evaluated by computed tomography
of the thorax, abdomen and pelvis and/or chest radiog-
raphy. The surgical resection (enucleation, wedge resection,
segmental resection and total/subtotal organ resection) of
the GIST was performed according to the tumor site
and size. All patients with gastric cancer underwent a D2
lymphadenectomy as described by the Japanese Classifica-
tion of Gastric Carcinoma (JCGC) [9]. The risk stratifica-
tion of GIST was according to the proposed modification
of the NIH consensus classification for GIST [10]. The
TNM stage of gastric cancer was based on the 7th edition
of UICC/TNM system [11]. Patients classified as inter-
mediate risk or high risk were suggested to receive 400 mg
of imatinib orally after the operation, taken once daily with
food, in the form of 100-mg capsules. The therapy was
usually given for about 2 years for the intermediate risk
and 3 years for the high risk.
The patients were followed up by trained investigators
by mail, email, telephone, visits to patients or consulta-
tions at the outpatient clinic. The last follow-up date
was February 2013. Survival duration was defined as the
interval between the date of operation to the date of last
contact, date of death, or date on which survival infor-
mation was collected (due, for example, to loss of con-
tact or death from other causes).
Statistical analysis
All statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS), version 18.0 for
Windows (SPSS Inc, Chicago, USA). Measurement data
were reported as means ± standard deviations, while enu-
merated data were assessed using the Chi-square or Fisher’s
exact test. Kaplan-Meier curves were used to estimate
overall survival time, with univariate comparisons between
groups through the log-rank test. Multivariate analysis
using the Cox model was used to evaluate independent
predictors of survival. A P value <0.05 was considered sta-
tistically significant.
Ethical approval
Ethics Committee of Fujian Medical University Union
Hospital approved this retrospective study. Written
consent was given by the patients for their informa-




In the 170 patients, there were 93 males and 77 females,
with a male to female ratio of 1.21:1. The mean age at diag-
nosis of GIST was 61.1 ± 12.0 years. For GIST, 52 patients
were classified as very low risk, 58 as low risk, 29 as inter-
mediate risk, and 31 as high risk. In the CA Group, thestaging of the synchronous gastric cancer was as follows:
14 patients were classified as Stage IA, 8 as Stage IB, 5 as
Stage IIA, 1 as Stage IIB, 7 as Stage IIIA, 4 as Stage IIIB,
and 3 as Stage IIIC. The histological subtype of the gastric
cancer was as follows: 6 patients were classified as well
differentiated, 21 as moderately differentiated, 10 as poorly
differentiated and 5 as signet ring cell (SRC) histology.
Compared with the Non-CA Group, the CA Group had a
higher percentage of males, was older in age, and had a
lower frequency of ulcer, a smaller greatest tumor diam-
eter, lower risk stratification, and lower positivity rates for
CD117 and CD34, with all of these differences being sta-
tistically significant (Table 1).
Diagnosis
Of the 146 (85.9%) symptomatic patients, 97 had abdom-
inal pain, 38 had abdominal tenderness, 33 had black
stool, 32 had abdominal distension, 30 had weight loss,
18 had eructation, 16 had anorexia, 16 had sour regurgi-
tation, 16 had hematemesis, 14 had an abdominal mass,
11 had a loss of strength, 11 had dysphagia, 7 had vomit-
ing and 6 had nausea. The proportion of patients with
symptoms was significantly higher in the CA than in the
Non-CA Group (P <0.05) (Table 1). Of the 97 patients
preoperatively diagnosed with gastric GIST, 50 were diag-
nosed by computed tomography, 38 by abdominal ultra-
sonography, 8 by magnetic resonance imaging, 2 by
gastroscopy, and 37 by endoscopic ultrasound, while 8 pa-
tients were confirmed to have the disease by endoscopic
biopsy pathology. GISTs in the remaining 73 patients were
detected incidentally during surgery or by postoperative
analysis of resected specimens, with patients being subse-
quently diagnosed with gastric GIST by postoperative
pathology. Of the 128 patients in the Non-CA group, 88
tumors (68.8%) were identified before surgery but not
confirmed by pathology, 8 (6.3%) were confirmed before
surgery and 32 (25.0%) were confirmed after surgery. In
the CA group, however, only 1 tumor (2.4%) was detected
before surgery, whereas 41 (97.6%) were confirmed after
surgery. The rate of preoperative diagnosis was signifi-
cantly lower in the CA than in the Non-CA Group (2.4%
versus 97.6%, P = 0.000) (Table 2).
Long-term surgical outcomes
Of the 170 patients, 165 (97.1%) were followed up for 2
to 127 months (median, 38 months), including 40 pa-
tients (95.2%) in the CA Group and 125 (97.7%) in the
Non-CA Group. During follow-up, 23 patients died, 14
in the CA and 9 in the Non-CA Group. The 3- and
5-year overall survival (OS) rates were 87.0% and 82.3%,
respectively, for the entire cohort, 62.6% and 57.8%, re-
spectively, for the CA group, and 94.8% and 90.1%, re-
spectively, for the Non-CA group. The between-group
differences were statistically significant (Figure 1).
Table 1 Clinicopathologic features of all patients (cases (%))









Greatest tumor diameter (cm) 0.000*
≤ 2 19(14.8) 35(83.3)
From >2 to 5 69(53.9) 7(16.7)







≤ 5/50 HPF 97(75.8) 38(90.5)
From >5 to 10/50 HPF 21(16.4) 3(7.1)
>10/50 HPF 10(7.8) 1(2.4)
Risk stratification 0.000*


















*Analysis of variance. P <0.05 is significant. CA Group, gastric GIST patients with synchronous gastric cancer; Non-CA Group, gastric GIST patients without
synchronous gastric cancer.
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Table 2 Diagnosis of all patients (cases (%))







*Analysis of variance. P <0.05 is significant. CA Group, gastric GIST patients
with synchronous gastric cancer; Non-CA Group, gastric GIST patients without
synchronous gastric cancer.
Table 3 Univariate analysis of variables associated with
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Univariate analysis showed that patient age, risk stratifi-
cation, postoperative oral imatinib and synchronous
gastric cancer were predictive factors of survival (P <0.05;
Table 3). Cox regression analysis showed that risk stratifi-
cation, postoperative oral imatinib and synchronous gas-
tric cancer were independent predictors of OS (P <0.05;
Table 4).
Survival analysis based on risk stratification
The 5-year survival rates were significantly lower among
patients with synchronous gastric cancer than among pa-
tients without synchronous gastric cancer, both among
patients stratified as being at very low risk/low risk (60.2%
versus 98.6%, P <0.05) and among those stratified asFigure 1 Kaplan-Meier estimates of overall survival rates.
Kaplan-Meier estimates of overall survival rates relative to the
presence or absence of synchronous gastric cancer in patients with
gastrointestinal stromal tumor (GIST) (n = 170, χ2 = 22.508, P = 0.000).
CA Group, gastric GIST patients with synchronous gastric cancer;














Synchronous gastric cancer 0.000*
Yes/No 42(57.8)/128(90.1)




Postoperative oral imatinib 0.009*
Yes/No 53(97.0)/117(77.3)
SRC, signet ring cell.
*Analysis of variance. P <0.05 is significant.
Table 4 Multivariate analysis of factors prognostic of survival in patients with gastric gastrointestinal stromal tumor
(GIST) and synchronous gastric cancer
Parameters β SE Wald P* RR 95% CI
Age −0.596 0.481 1.531 0.551 0.215-1.416
Synchronous gastric cancer −2.296 0.602 14.571 0.000* 0.101 0.031-0.327
Risk stratification 24.190 0.000*
Very low versus high −2.504 0.607 17.001 0.000* 0.082 0.025-0.269
Low versus high −2.544 0.682 13.895 0.000* 0.079 0.021-0.299
Intermediate versus high −2.638 1.060 6.191 0.013* 0.071 0.009-0.571
Postoperative oral imatinib 2.213 1.045 4.489 0.034* 9.146 1.180-70.864
*Analysis of variance. P <0.05 is significant.
Figure 2 Kaplan-Meier estimates of overall survival rates based
on risk stratification. Kaplan-Meier estimates of overall survival rates
in gastric gastrointestinal stromal tumor (GIST) patients with and
without synchronous gastric cancer and at (A) very low/low risk
(n = 110, χ2 = 22.800, P = 0.000) and at (B) intermediate/high risk
(n = 60, χ2 = 11.123, P = 0.001).
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P <0.05) (Figure 2).
Discussion
The incidence of GIST is only approximately 10 to 20
cases per million per year, [12-16] with gastric GIST be-
ing the most common type. Although GISTs are rare,
the proportion of GIST patients who present synchron-
ously with other malignancies is not low. In particular,
the combination of gastric GIST and synchronous gastric
cancer is relatively common. An analysis of 14 studies
found that 4.5% to 33% of patients had GIST simultan-
eously with other neoplasms [17]. In our series we found
that 42 of 170 (24.7%) patients with gastric GISTs pre-
sented with synchronous gastric cancers. Gastric GISTs
accompanied by synchronous gastric cancer have spe-
cific pathological features. For example, 14 of 15 gastric
GISTs with synchronous gastric cancer were smaller than
2.0 cm in size, with the fifteenth being 2.5 cm; moreover,
almost all of these tumors were stratified as very low or
low risk [2]. Similarly, we found that most of the gastric
GISTs in patients with synchronous gastric cancer were
small and of very low or low risk of malignancy. Moreover,
only one of the 42 patients (2.4%) found to have gastric
GIST with synchronous gastric cancer was diagnosed pre-
operatively, with all others detected incidentally during
surgery or in postoperative pathology, a finding in agree-
ment with previous results [1,2,18].
Clinical manifestations of gastric GIST were nonspecific,
with some patients having no clinical manifestations when
the tumor was small. The preoperative diagnosis of GIST
depended mainly on imaging modalities, such as com-
puted tomography and endoscopy [19,20]. In patients with
simultaneous gastric cancer and gastric GIST, the symp-
toms of gastric GIST were often masked by the clinical
symptoms of gastric cancer. Most of these patients had
small GISTs (<2.0 cm) and saw a doctor for the symptoms
of gastric cancer. Moreover, since most gastric GISTs
were submucosal, muscular, or subserosal, patients often
could not be preoperatively diagnosed by endoscopic bi-
opsy. Furthermore, many clinicians lack the knowledge of
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of gastric cancer alone, resulting in a low rate of preopera-
tive diagnosis of gastric GIST.
Interestingly, we found that the gastric GIST patients
with synchronous gastric cancer were older in age com-
pared with those without synchronous gastric cancer,
and that was a predictive factor of survival. However, the
age was not an independent predictor of OS. We specu-
lated that the finding might be associated with the high
incidence of gastric cancer in older patients. In addition,
the elderly might be with some change of gene expression
profile and a lower immunity, resulting in more easily
suffering from the synchronous tumors. Further stud-
ies are needed on the gene expression in primary tumor
cells from older and younger patients and signal transduc-
tion may also provide us with some clues to this finding.
Common immunohistochemistry included CD117, CD34,
SMA, S-100 of GIST were analyzed in our study, where
we found statistically different positive rates of CD117 and
CD34 between groups. However, further prognosis ana-
lysis suggested this finding was not related to prognosis.
We found that the gastric GIST with synchronous gastric
cancer had a lower positive rate of CD117 and CD34
based on the large sample. This was a finding not encoun-
tered before in the literature. It might be worth forming
a base of classification of GIST tumors according to it.
More research is needed.
Previously, GIST was associated with a poor prognosis,
with 5-year OS rates after R0 resection ranging from 28%
to 65%, [21-25] and another study reporting that patients
with gastric GIST had a 5-year OS rate of 42% [26]. Add-
itional studies, improvements in surgical skill, and the intro-
duction of the molecular targeted drug imatinib have
significantly improved the prognosis of patients with GIST,
with a study in 2010 reporting a 5-year OS rate in 187
patients with gastric GIST being 75.9% [27]. Few studies
to date have assessed the prognosis of patients with syn-
chronous gastric GIST and gastric cancer. A study of
22 patients with gastric GIST and synchronous gastric
cancer who underwent surgical treatment found that
the 5-year OS rate was 57.8%, with a median survival
time of 36 months [28]. We found that the 5-year OS rate
in patients was significantly lower in gastric GIST patients
with than without gastric cancer. Furthermore, risk strati-
fication and the presence of synchronous gastric cancer
were independent predictors of survival. The prognosis of
gastric GIST patients was reported to be poorer for those
with synchronous gastric cancer than for those without
synchronous gastric cancer, regardless of risk stratification
[4]. Similarly, we found that the 5-year OS rates were sig-
nificantly lower in patients with synchronous gastric can-
cer than in those without synchronous gastric cancer,
whether patients were stratified into the very low/low risk
or intermediate/high risk groups. Thus, because of smallertumor size, lower risk stratification and lower recurrence
risk after complete resection, the prognosis of gastric
GIST patients with synchronous gastric cancer was good,
with GIST itself having little effect on patient prognosis.
The main cause of poor prognosis in these patients was
advanced synchronous gastric cancer, suggesting that ac-
tive treatment of the synchronous gastric cancer would
improve long-term survival of these patients.
Some studies revealed that SRC histology was associated
with worse survival than non-SRC [29-31]. In our study,
there were 5 patients with SRC carcinoma in the syn-
chronous gastric cancer. To study the importance of SRC
histology on survival, univariate analysis was done in the
gastric GIST patients with SRC or with non-SRC, with a
result of no significant differences. But the result might be
of limitation of the small sample. Previous reports of the
prognosis of patients with SRC were controversial. Some
studies reported better 5-year survival rates in SRC than
in other cell types in early gastric cancer [32,33]. However,
others reported no significant differences when the stage
of gastric cancer matched [34]. It has also been suggested
that SRC histology is an independent predictor of poor
prognosis in gastric cancer [29].
All GISTs are regarded as having malignant poten-
tial. Moreover, in patients with gastric GIST and syn-
chronous gastric cancer, larger sized GISTs and higher
risk stratification were associated with a high recurrence
rate and poor prognosis, even after complete resection of
the GIST [35]. Consequently, gastric GIST should be re-
moved when incidentally discovered during surgery for
gastric cancer; when necessary, targeted therapy should be
considered.
Conclusions
Gastric GIST with synchronous gastric cancer had a
lower rate of preoperative diagnosis, with correct diag-
nosis often missed. Survival, however, depended primar-
ily on the gastric cancer, suggesting that active treatment
of the synchronous gastric cancer would improve long-
term survival of these patients. Moreover, gastric GISTs
should be removed when incidentally discovered during
surgery for gastric cancer; when necessary, targeted ther-
apy should be considered.
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